Valeo Financial Advisors LLC Decreases Stock Position in Zoetis Inc. $ZTS

Valeo Financial Advisors LLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 29.3% in the second quarter, HoldingsChannel reports. The institutional investor owned 5,010 shares of the company’s stock after selling 2,081 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Zoetis were worth $781,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Nuveen LLC purchased a new stake in Zoetis in the first quarter valued at about $616,375,000. Mackenzie Financial Corp increased its holdings in shares of Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after purchasing an additional 1,782,110 shares during the period. Polen Capital Management LLC increased its holdings in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Amundi increased its holdings in shares of Zoetis by 30.8% in the first quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after purchasing an additional 846,909 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its holdings in shares of Zoetis by 475.9% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after purchasing an additional 743,926 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.6%

Zoetis stock opened at $143.61 on Thursday. The firm has a market cap of $63.65 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 2.29 and a beta of 0.90. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The business’s 50-day moving average price is $149.41 and its 200 day moving average price is $154.74. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ZTS. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Argus reissued a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Finally, Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.